WHIPPANY, New Jersey – (COMMERCIAL THREAD) – Patient organization ZERO – The End of Prostate Cancer and Bayer team up to launch We are not going to take it – a national prostate cancer education program with guitarist Jay Jay French, founding member of heavy metal band Twisted Sister. The rocker was diagnosed with prostate cancer in 2018 and now he is urging men to volume up against prostate cancer to detect this disease at an early stage. The campaign encourages men to get tested for prostate cancer and to learn more about risk factors, such as family history and high levels of prostate specific antigen (PSA).2 For men already diagnosed with prostate cancer, the program offers information to help better understand the diagnosis and available treatment options. As part of the campaign, ZERO, Bayer and Jay Jay French encourage men and their loved ones to visit ZERO’s website, which includes the “Prostate Cancer Uncensored” podcast where Jay Jay shares his story and the Truth or Twisted Quiz separate fact from fiction when it comes to prostate cancer.
“My father died of prostate cancer in 1984 and because of the family history my doctors were looking for this disease in me and my brother, ”French said. “I am a prostate cancer survivor because my doctors have been proactive, and I work with ZERO and Bayer to encourage men 50 and older, especially those with a family history of the disease, to become advocates. of themselves, to get checked every year and find out if their PSA number is up.
“All men are at risk for prostate cancer and screening and early detection is the best defense against this disease, ”said Jamie Bearse, CEO and President of ZERO. “Understanding the family history and other risk factors is an important step in knowing when to start screening for prostate cancer.
If an elevated PSA level is identified early, there are treatment options that extend survival.3 It is important that men are educated about the different treatment options and their side effect profiles so that they can have informed treatment conversations with their doctor. We are not going to take it seeks to educate men about treatment options, so they can defend themselves.
“We are proud to work alongside ZERO and Jay Jay French to help support the exceptional work being done to educate men about prostate cancer, ”said Nelson Ambrogio, senior vice president, general manager, Oncology at Bayer. “Through science, innovation and research, Bayer is committed to transforming the treatment of prostate cancer, with the goal of delivering significant benefits so men can live longer.
About the National Prostate Cancer Education Campaign
We are not going to take it is a national education campaign to raise awareness of the importance of screening and early detection of prostate cancer. With the support of Bayer, ZERO is proud to partner with Jay Jay French – guitarist, manager, record producer and founding member of heavy metal band Twisted Sister. Rock and Roller is a prostate cancer survivor and national spokesperson for the education campaign designed to motivate men to take action against prostate cancer, to learn about risk factors, such as history families of the disease, and understand their treatment options. As part of the campaign, ZERO, Bayer and Jay Jay French encourage men and their loved ones to visit ZERO’s website, which includes the “Prostate Cancer Uncensored” podcast where Jay Jay shares his story and the Truth or Twisted Quiz separate fact from fiction when it comes to prostate cancer.
About prostate cancer
Prostate cancer is the second most commonly diagnosed malignant tumor in men worldwide.4 In 2020, approximately 192,000 men in the United States were diagnosed with prostate cancer and approximately 33,000 died from the disease.5 Prostate cancer is the fifth leading cause of cancer death in men.4 Prostate cancer results from the abnormal proliferation of cells in the prostate, which is part of the male reproductive system.1 It mainly affects men over 50 and the risk increases with age.6
About Oncology at Bayer
Bayer is committed to providing science for a better life by offering a portfolio of innovative treatments. Bayer’s oncology franchise includes six marketed products and several other assets in various stages of clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways that may impact how cancer is treated.
About Bayer
Bayer is a global company with core competencies in the fields of life sciences, healthcare and nutrition. Its products and services are designed to help people and the planet prosper by supporting efforts to address the major challenges presented by a growing and aging global population. Bayer is committed to promoting sustainable development and generating a positive impact with its activities. At the same time, the Group aims to increase its profitability and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality around the world. In fiscal year 2020, the Group employed around 100,000 people and generated sales of € 41.4 billion. R&D expenses before exceptional items amounted to 4.9 billion euros. For more information, visit www.bayer.com.
About ZERO – The end of prostate cancer
ZERO – The End of Prostate Cancer is the leading national nonprofit organization with a mission to end prostate cancer. ZERO advances research, improves the lives of men and families and inspires action. ZERO is building Generation ZERO, the first generation of men freed from prostate cancer, through our national run / walk series, patient education and support programs, and community advocacy. ZERO is a Charity Navigator accredited 501 (c) (3) philanthropic organization with four out of four stars, accredited by the Better Business Bureau, with regional chapters across the country. ZERO spends 85 cents of every dollar on research and programs. For more information visit www.zerocancer.org.
© 2021 Bayer
BAYER and La Croix Bayer are registered trademarks of Bayer. All other trademarks belong to their respective owners.
Forward-looking statements
This press release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various risks, uncertainties and other known and unknown factors could cause material differences between the actual future results, financial condition, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on Bayer’s website at www.bayer.com. The company assumes no responsibility for the updating of these forward-looking statements or their compliance with future events or developments.
The references
-
American Cancer Society. What is prostate cancer? https://www.cancer.org/content/dam/CRC/PDF/Public/8793.00.pdf. Accessed June 2021.
-
Cleveland Clinic. High level of PSA (prostate specific antigen). https://my.clevelandclinic.org/health/diseases/15282-elevated-psa-prostate-specific-antigen-level. Accessed June 2021.
-
American Society of Clinical Oncology. Chronology of cancer progress. Prostate cancer. https://www.asco.org/research-guidelines/cancer-progress-timeline/prostate-cancer. Accessed June 2021.
-
GLOBOCAN 2018: Estimated incidence, mortality and prevalence of cancer in the world in 2018. Prostate cancer. https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21492. Accessed June 2021.
-
American Cancer Society. Cancer facts and figures 2020. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020. pdf. Accessed June 2021.
-
American Cancer Society. Risk factors for prostate cancer. https://www.cancer.org/content/dam/CRC/PDF/Public/8794.00.pdf. Accessed June 2021.
PP-PF-ONC-US-1948-1 | 06/21
